Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MDD011
MIFTS: 63

Mood Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mood Disorder

About this section

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 15
Mood Disorders 55 43 44 73
Episodic Mood Disorder 12 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3324
MeSH 44 D019964
NCIt 50 C92200
Sources

Summaries for Mood Disorder

About this section
MedlinePlus : 43 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to delusional disorder and dysthymic disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is DISC2 (Disrupted In Schizophrenia 2
DISC2 is a likely susceptibility locus for both schizophrenia and affective disorders.
Dysfunction Pattern: ), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Amitriptyline and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 76 Mood disorder, also known as mood (affective) disorders, is a group of conditions where a disturbance in... more...

Sources

Related Diseases for Mood Disorder

About this section

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 delusional disorder 33.2 DRD2 DRD4 TH
2 dysthymic disorder 32.8 HTR2A MAOA SLC6A4
3 atypical depressive disorder 32.5 CRH MAOA SLC6A4
4 acth-secreting pituitary adenoma 32.5 CRH NR3C1 POMC
5 postpartum depression 32.4 BDNF COMT CRH HTR1A MAOA SLC6A4
6 endogenous depression 32.0 BDNF CRH MAOA POMC SLC6A4
7 schizoaffective disorder 32.0 BDNF COMT DISC1 DISC2 DRD2 HTR2A
8 tardive dyskinesia 31.4 COMT DRD2 HTR2A
9 alexithymia 30.9 COMT DRD2 HTR1A SLC6A4
10 social phobia 30.9 DRD2 HTR1A MAOA SLC6A4
11 alcohol abuse 30.9 BDNF DRD2 DRD4 SLC6A4
12 bipolar i disorder 30.9 BDNF COMT HTR1A HTR2A SLC6A4
13 kleptomania 30.9 HTR1A MAOA SLC6A4
14 traumatic brain injury 30.8 BDNF COMT DRD2
15 pathological gambling 30.8 DRD2 DRD4 HTR2A MAOA SLC6A4
16 brain injury 30.8 BDNF COMT DRD2
17 schizophreniform disorder 30.7 COMT DRD2
18 temporal lobe epilepsy 30.7 BDNF HTR1A NPY
19 cocaine dependence 30.6 DRD2 POMC SLC6A4
20 fibromyalgia 30.6 COMT CRH HTR2A NPY SLC6A4
21 autism spectrum disorder 30.5 BDNF DISC2 HTR2A SLC6A4
22 tobacco addiction 30.4 COMT DRD2 HTR2A MAOA TPH1
23 substance abuse 30.2 BDNF COMT DRD2 DRD4 HTR1B MAOA
24 substance dependence 30.2 BDNF DRD2 DRD4 HTR1B MAOA POMC
25 eating disorder 30.2 BDNF COMT CRH DRD2 NPY POMC
26 paranoid schizophrenia 30.0 BDNF COMT HTR2A MAOA SLC6A4 TPH2
27 generalized anxiety disorder 30.0 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
28 narcolepsy 30.0 COMT DRD2 HTR2A SLC18A2 TPH1
29 depression 29.8 BDNF CRH DISC2 HTR1A HTR2A MAOA
30 post-traumatic stress disorder 29.7 BDNF COMT CRH DRD2 HTR2A MAOA
31 asthma 29.6 BDNF CREB1 CRH NPY NR3C1 POMC
32 anxiety 29.5 BDNF COMT CRH HTR1A HTR2A MAOA
33 personality disorder 29.2 BDNF COMT DRD2 DRD4 HTR1A HTR1B
34 borderline personality disorder 29.2 BDNF COMT HTR1A HTR1B HTR2A MAOA
35 major depressive disorder 29.0 BDNF COMT CREB1 CRH DISC1 DISC2
36 bipolar disorder 29.0 BDNF COMT CREB1 CRH DISC1 DISC2
37 panic disorder 29.0 BDNF COMT CRH HTR1A HTR2A MAOA
38 schizophrenia 28.9 BDNF COMT DISC1 DISC2 DRD2 DRD4
39 autism 28.9 BDNF COMT DISC1 DRD2 DRD4 HTR1A
40 obsessive-compulsive disorder 28.9 BDNF COMT DRD2 DRD4 HTR1A HTR1B
41 psychotic disorder 28.7 BDNF COMT DISC1 DRD2 DRD4 HTR1A
42 attention deficit-hyperactivity disorder 27.9 BDNF COMT DRD2 DRD4 HTR1A HTR1B
43 alcohol dependence 27.7 BDNF COMT DRD2 DRD4 HTR1A HTR1B
44 alzheimer disease 5 11.1 HTR2A SLC6A4
45 organic mood syndrome 11.0
46 psychosexual disorder 11.0 HTR1A HTR2A SLC6A4
47 polycystic ovary syndrome 11.0
48 asperger syndrome 11.0
49 schizoid personality disorder 11.0 HTR1A HTR2A
50 alcoholic psychosis 11.0 DRD2 HTR2A SLC6A4

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder
Sources

Symptoms & Phenotypes for Mood Disorder

About this section

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 TH TPH1 TPH2 BDNF DISC1 COMT
2 homeostasis/metabolism MP:0005376 10.36 TH TPH1 TPH2 CRH BDNF DISC1
3 cardiovascular system MP:0005385 10.31 TH TPH1 TPH2 COMT DRD2 CREB1
4 growth/size/body region MP:0005378 10.3 TH TPH1 TPH2 SLC6A4 CRH BDNF
5 endocrine/exocrine gland MP:0005379 10.22 TH SLC6A4 CRH BDNF COMT DRD2
6 nervous system MP:0003631 10.22 TH TPH2 BDNF DISC1 COMT DRD2
7 adipose tissue MP:0005375 10.13 TPH1 TPH2 CRH DRD2 HTR1B POMC
8 integument MP:0010771 10.06 TH TPH1 SLC6A4 TPH2 CRH BDNF
9 muscle MP:0005369 9.97 TPH1 SLC6A4 DRD2 CREB1 NR3C1 HTR1B
10 no phenotypic analysis MP:0003012 9.91 TH TPH2 CRH BDNF DRD2 HTR1B
11 normal MP:0002873 9.81 TH SLC6A4 TPH2 CRH BDNF DRD2
12 respiratory system MP:0005388 9.61 TH TPH1 TPH2 CRH BDNF COMT
13 taste/olfaction MP:0005394 8.92 TPH2 BDNF DRD2 SLC18A2
Sources

Drugs & Therapeutics for Mood Disorder

About this section

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 745)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
2
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
4
Nortriptyline Approved Phase 4,Phase 1,Phase 2,Not Applicable 72-69-5 4543
5
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
6
Perphenazine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-39-9 4748
7
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
8
Trimipramine Approved Phase 4 739-71-9 5584 4055
9
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
11
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
12
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
13
Cycloserine Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-41-7 401 6234
14
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54910-89-3 3386
15
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
16
Methyltestosterone Approved Phase 4,Phase 3,Not Applicable 58-18-4 6010
17
Testosterone Approved, Investigational Phase 4,Phase 3,Not Applicable 58-22-0 6013
18
Testosterone enanthate Approved Phase 4,Phase 3,Not Applicable 315-37-7 9416
19
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Not Applicable 5949-44-0
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75614-87-8, 51-45-6 774
21
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 24219-97-4 4184
22
Mirtazapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 85650-52-8, 61337-67-5 4205
23
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
24
Fluvoxamine Approved, Investigational Phase 4,Phase 2,Not Applicable 54739-18-3 3404 5324346
25
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 19794-93-5 5533
26
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
27
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
28
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
29
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
30
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
31
Ropinirole Approved, Investigational Phase 4,Not Applicable 91374-20-8, 91374-21-9 5095 497540
32
Copper Approved, Investigational Phase 4,Not Applicable 7440-50-8 27099
33
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
34 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
35
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
36
Norethindrone Approved Phase 4 68-22-4 6230
37
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
38
Diphenhydramine Approved, Investigational Phase 4,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
39
Promethazine Approved, Investigational Phase 4,Phase 1,Not Applicable 60-87-7 4927
40
Suvorexant Approved, Investigational Phase 4 1030377-33-3
41
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
42
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
43
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
44
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 98769-81-4, 71620-89-8 123628 65856
45
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 132539-06-1 4585
46
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
47
Tranylcypromine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 155-09-9 441233
48
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
49
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 298-46-4 2554
50
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10118-90-8 5281021

Interventional clinical trials:

(show top 50) (show all 3978)
# Name Status NCT ID Phase Drugs
1 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
2 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
3 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
4 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
6 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
7 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
8 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
9 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
10 Lexapro®'s Efficacy After Dose Escalation in Remission Study Unknown status NCT01594866 Phase 4 escitalopram;escitalopram
11 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
12 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
13 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
14 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
15 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
16 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
17 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
18 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
19 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
20 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
21 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
22 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
23 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
24 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
25 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
26 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
27 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
28 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
29 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
30 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
31 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
32 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
33 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
34 Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder Unknown status NCT02129751 Phase 4 bupropion hydrobromide;Placebo
35 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
36 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
37 Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder Unknown status NCT01696617 Phase 4 Aripiprazole 6-week group;Aripiprazole 8-week group
38 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
39 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
40 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
41 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
42 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
43 Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
44 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
45 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
46 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
47 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
48 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
49 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
50 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: mood disorders

Sources

Genetic Tests for Mood Disorder

About this section
Sources

Anatomical Context for Mood Disorder

About this section

MalaCards organs/tissues related to Mood Disorder:

41
Brain, Heart, Testes, Cortex, Pituitary, Bone, Thyroid
Sources

Publications for Mood Disorder

About this section

Articles related to Mood Disorder:

(show top 50) (show all 863)
# Title Authors Year
1
Risk profiles of personality traits for suicidality among mood disorder patients and community controls. ( 29141103 )
2018
2
Decreased functional connectivity in the fronto-parietal network in children with mood disorders compared to children with dyslexia during rest: An fMRI study. ( 29845006 )
2018
3
A Review on the General Stability of Mood Disorder Diagnoses Along the Lifetime. ( 29607445 )
2018
4
Gut-Brain Axis and Mood Disorder. ( 29896129 )
2018
5
Food addiction, in obese patients seeking bariatric surgery, is associated with higher prevalence of current mood and anxiety disorders and past mood disorders. ( 29980127 )
2018
6
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
7
Epigenetics of Metabolic Syndrome as a Mood Disorder. ( 29707086 )
2018
8
The association between social skills deficits and family history of mood disorder in bipolar I disorder. ( 29590265 )
2018
9
BDNF signaling: Harnessing stress to battle mood disorder. ( 29592951 )
2018
10
Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety. ( 29543103 )
2018
11
Anxiety and Mood Disorder in Children With Autism Spectrum Disorder and ADHD. ( 29602900 )
2018
12
The association between low level of high-density lipoprotein cholesterol and mood disorder using time-dependent analysis. ( 28843914 )
2018
13
Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders. ( 29808011 )
2018
14
Symptom Profile of Psychiatric Patients With Psychosis or Psychotic Mood Disorder in Prison. ( 29426253 )
2018
15
Using Neuroimaging to Develop Mood Disorder Diagnostic Biomarkers: A Good Forward Step and Some Considerations. ( 29735151 )
2018
16
Design of FRET Probes for SNP RS1006737, Related to Mood Disorder. ( 29541152 )
2018
17
Independent associations and effect modification between lifetime substance use and recent mood disorder diagnosis with household food insecurity. ( 29360862 )
2018
18
Effect of Hypoxic Injury in Mood Disorder. ( 28717522 )
2017
19
Creativity and Mood Disorder: A Systematic Review and Meta-Analysis. ( 28934560 )
2017
20
Chronobiological theories of mood disorder. ( 28894915 )
2017
21
Facilitators and Barriers to Disclosure of Postpartum Mood Disorder Symptoms to a Healthcare Provider. ( 28766092 )
2017
22
Could EPO studies improve mood disorder treatment strategies? ( 27967254 )
2017
23
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. ( 28839340 )
2017
24
Mood Disorder as an Early Presentation of Epidermoid of Quadrigeminal Cistern. ( 28694630 )
2017
25
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017
26
Heterozygosity for the Mood Disorder-Associated Variant Gln460Arg Alters P2X7 Receptor Function and Sleep Quality. ( 29079688 )
2017
27
Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )
2017
28
Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. ( 28658442 )
2017
29
Defective compensation over early dysneurogenesis in schizophrenia and mood disorder. ( 28666634 )
2017
30
Is the association between offspring intelligence and parents' educational attainment influenced by schizophrenia or mood disorder in parents? ( 28868239 )
2017
31
Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy. ( 28845834 )
2017
32
Defining melancholia: A core mood disorder. ( 28599349 )
2017
33
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder. ( 28686107 )
2017
34
Analyzing the Effect of V66M Mutation in BDNF in Causing Mood Disorders: A Computational Approach. ( 28427565 )
2017
35
Genealogy Study of Three Generations of Patients with Bipolar Mood Disorder Type I. ( 28852243 )
2017
36
Direct Involvement of Androgen Receptor in Oxytocin Gene Expression: Possible Relevance for Mood Disorders. ( 28447621 )
2017
37
Environmental perturbation of the circadian clock during pregnancy leads to transgenerational mood disorder-like behaviors in mice. ( 28974783 )
2017
38
Exploratory Study of the Clinical Characteristics of Adolescent Girls with a History of Physical or Sexual Abuse Consulting in a Mood Disorder Clinic. ( 28747935 )
2017
39
The impact of schizophrenia and mood disorder risk alleles on emotional problems: investigating change from childhood to middle age. ( 29239291 )
2017
40
Narcissistic Personality Disorder and suicidal behavior in mood disorders. ( 27816770 )
2017
41
Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. ( 28612214 )
2017
42
Prolonged delirium misdiagnosed as a mood disorder. ( 29213513 )
2017
43
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. ( 28681620 )
2017
44
Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. ( 28898408 )
2017
45
Effectiveness evaluation of mood disorder treatment algorithms in Brazilian public healthcare patients. ( 28832750 )
2017
46
The interaction of GSK3B and FXR1 genotypes may influence the mania and depression dimensions in mood disorders. ( 28242499 )
2017
47
Comparing the Profile of Temperament and Character Dimensions in Patients with Major Depressive Disorder and Bipolar Mood Disorder with a Control Group. ( 29062365 )
2017
48
Prevalence and predictors of post-stroke mood disorders: A meta-analysis and meta-regression of depression, anxiety and adjustment disorder. ( 28807138 )
2017
49
Effect of lithium on thyroid function in adolescents with mood disorder. ( 27931904 )
2016
50
Functioning Among Youth with Comorbid Mood Disorder and Chronic Physical Illness in Public Sector Care. ( 27680986 )
2016
Sources

Variations for Mood Disorder

About this section
Sources

Expression for Mood Disorder

About this section
Search GEO for disease gene expression data for Mood Disorder.
Sources

Pathways for Mood Disorder

About this section

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.49 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2
G-Beta Gamma Signaling 64
Show member pathways
 12.93 BDNF CREB1 CRH DRD2 HTR2A POMC
3
Circadian entrainment 37
Show member pathways
 12.92 COMT CREB1 DRD2 DRD4 MAOA SLC18A2
4
Neuroscience 4
12.46 COMT CREB1 HTR1A NPY POMC TH
5
cAMP signaling pathway 37
Show member pathways
 12.21 BDNF CREB1 DRD2 HTR1A HTR1B NPY
7
Monoamine GPCRs 1
Show member pathways
 11.92